Cold-attenuated live influenza vaccines, a risk-benefit assessment.

  title={Cold-attenuated live influenza vaccines, a risk-benefit assessment.},
  author={Michael Pfleiderer and Johannes Loewer and Reinhard Kurth},
  volume={20 5-6},
The principle of live attenuated influenza vaccines has been known for many decades. However, the pharmaceutical and clinical development according to current regulations, of modern live influenza vaccines based on cold adapted influenza viruses (CAIV) started only recently and these vaccines will most probably become an alternative within the next couple of years to licensed inactivated influenza vaccines that have been used routinely since the early 1940s. In contrast to contemporary… CONTINUE READING